Biotechnology - Genomic and Proteomics/IP Profile of Biggest for-profit companies in BGP/BGP Company Profiles - Data

From Commons Based Research
Jump to navigation Jump to search

NIH

Celera

Amgen

Who

  • 16,900 employees (2008 Corporate report)
  • History of acquisition (http://www.amgen.com/about/acquisitions.html):
    • 1994 - Synergen, Inc.
    • 2000 - Kinetix Pharmaceuticals, Inc.
    • 2002 - Immunex Corporation
    • 2004 - Tularik, Inc.
    • 2006 - Abgenix, Inc.
    • 2006 - Avidia, Inc.
    • 2007 - Ilypsa, Inc.
    • 2007 - Alantos Pharmaceuticals Holdings, Inc.
  • Subsidiaries (http://www.fundinguniverse.com/company-histories/Amgen-Inc-Company-History.html):
    • Amgen Australia Pty Ltd.;
    • Amgen N.V.; Amgen Canada Inc.;
    • Amgen Greater China Ltd.;
    • Amgen GmbH (Germany);
    • Amgen S.A. (France);
    • Amgen S.p.A. (Italy);
    • Amgen K.K. (Japan);
    • Amgen B.V. (Netherlands);
    • Amgen-Biofarmaceutica (Portugal);
    • Amgen S.A. (Spain);
    • Amgen (Europe) AG (Switzerland);
    • Kirin-Amgen, Inc. (Switzerland);
    • Amgen Limited (U.K.);
    • Amgen Sales Corporation (West Indies).
  • Unlike many biotech companies, has been consistently profitable. Net profit in 2006 was US$2.9Billion (http://www.pharmaceutical-business-review.com/companyprofile.asp?guid=8632C7AC-1633-4198-8551-BB79570C668D)
  • Managed to turn itself from a drug research company into a pharmaceutical company while maintaining steady sales - extremely rare in the industry (http://www.fundinguniverse.com/company-histories/Amgen-Inc-Company-History.html)
    • Founded in 1980. By 1986 was starting to turn a profit, but did so not through drug development but through research partnerships with established pharma firms
    • 1987, develop erythropoietin (EPO), which stimulates red blood cell creation. Sold the marketing rights to Johnson&Johnson
    • Epogen proves to hugely popular - over $250m in sales in 1991 alone
    • Between 1992 and 1996, Amgen's R&D budget goes from $182 million to $663 million

What

  • ten approved drugs for 15 conditions, 23 agents are being tested earlier in the approval pipeline
    • drugs include: Epogen, Aranesp, Enbrel, Kineret, Neulasta, Neupogen, Sensipar / Mimpara and Nplate
  • As a side-result of this research, also publishes in academic journals (e.g. http://en.scientificcommons.org/40666678)

Where

  • Thousand Oaks, CA

News

Commons-Based, Peer-Production, and Open Access News

Who

What

Where

  • South San Francisco

News

Commons-Based, Peer-Production, and Open Access News

Genzyme

Gilead Sciences

Biogen Idec

Cephalon

MedImmune

Celgene

Abraxis BioScience

ImClone Systems

Navigation

IP Profile of Biggest for-profit companies in BGP

Biotechnology - Genomic and Proteomics

Main Page